Takeda en las noticias
Transformando vidas a través de la ciencia
Tamtam encontró 20 artículos recientes sobre Takeda.
- Innovent stock gets USD 1.2 billion Takeda oncology deal
- Takeda Says Samsung Biosimilar Plans Infringe Entyvio IP
- International Plasma Awareness Week 2026: Takeda and Indonesia’s Health Ministry to raise plasma awareness
- Ghana’s Prof. Priscilla Kolibea Mante Leads KNUST Team to Secure $5.1 Million Takeda Global CSR Award
- Takeda’s zasocitinib raises bar for oral psoriasis drugs
- A Takeda spinout builds case for its Parkinson’s drug
- Takeda stock after-hours: prior close at EUR 15.55
- Should Phase 3 Psoriasis Win Require Action From Takeda Stock Investors?
- Takeda partners with Innovent: what USD 1.20 billion means for Innovent Biologics stock
- Takeda Pharmaceuticals' Psoriasis Pill Zasocitinib
- Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal
- Corus International receives $6.4 million grant from Takeda to reduce climate-related health risks in Nepal
- Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued After Fresh Psoriasis Trial Data
- Takeda Pharmaceuticals (NYSE:TAK): The Only Japanese Pharma Now Enters The Three Years That Will Define Its Future
- Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run
- Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data
- Takeda Pharmaceutical: Reimagining R&D With AI
- Allana Sanborn Steps Into New Role at Takeda Oncology
- Takeda details Phase 3 psoriasis comparison with Sotyktu
- Takeda (TAK) Reports Positive Phase 3 Data for Zasocitinib in Pl
Artículos recopilados por Tamtam y conservados cuando tratan sobre la empresa, del más reciente al más antiguo. Cada uno enlaza con su fuente.
¿Vendes a empresas como Takeda?
Tamtam encuentra las empresas que encajan con tu cliente ideal, investiga cada cuenta y te dice a quién contactar y cuándo.
Encontrar empresas similares